The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship
Author:
Funder
Eli Lilly and Company
Novartis Pharma
Publisher
Elsevier BV
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference141 articles.
1. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes;Drucker;Lancet.,2006
2. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors;Nauck;Diabetes, obesity & metabolism.,2016
3. Occurrence of nausea,vomiting and diarrhea reported as adverse events in clinical trials studyingglucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials;Bettge;Diabetes, obesity & metabolism,2017
4. Do GLP-1-based therapies increase cancer risk?;Nauck;Diabetes care,2013
5. Liraglutide and cardiovascular outcomes in type 2 diabetes;Marso;The New England journal of medicine.,2016
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy;Diabetologia;2023-08-19
2. GLP-1 analogues in therapy of obese adolescents. Early real-life experience with liraglutide treatment;Česko-slovenská pediatrie;2023-06-23
3. Circulating levels of gastrointestinal hormones in prediabetes reversing to normoglycemia or progressing to diabetes in a year–A cross-sectional and prospective analysis;Diabetes Research and Clinical Practice;2023-05
4. Research progress on the effects of novel hypoglycemic drugs in diabetes combined with myocardial ischemia/reperfusion injury;Ageing Research Reviews;2023-04
5. The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes;Cell Metabolism;2023-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3